KMDA KAMADA LTD IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1567529 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $44.68M | $47.01M | $44.75M | $44.02M | $39.01M | $41.74M | $42.47M | $37.74M |
| Cost of revenue | $27.71M | $27.25M | $25.82M | $23.27M | $21.97M | $24.51M | $23.52M | $20.98M |
| Gross profit | $16.97M | $19.76M | $18.93M | $20.75M | $17.03M | $17.23M | $18.95M | $16.75M |
| R&D expense | $2.89M | $2.64M | $3.22M | $4.25M | $2.67M | $3.41M | $4.80M | $4.29M |
| SG&A expense | $5.64M | $4.82M | $4.07M | $4.20M | $4.12M | $4.01M | $3.78M | $3.79M |
| Operating income | $3.55M | $7.82M | $7.07M | $7.79M | $5.08M | $5.29M | $5.64M | $4.04M |
| Interest expense | $259,000 | $221,000 | $192,000 | $192,000 | $4.76M | $167,000 | $145,000 | $159,000 |
| Pretax income | $4.73M | $6.37M | $5.75M | $6.61M | $2.46M | $3.95M | $4.49M | $2.44M |
| Income tax | $1.17M | $1.07M | -$1.62M | $2.65M | -$1.35M | $84,000 | $63,000 | $74,000 |
| Net income | $3.56M | $5.30M | $7.38M | $3.96M | $3.81M | $3.86M | $4.43M | $2.37M |
| EBITDA | -$5.93M | $11.58M | $10.82M | $11.41M | $9.18M | $8.54M | $8.87M | $7.28M |
| EPS (basic) | — | 0.09 | 0.13 | 0.07 | — | 0.07 | 0.08 | 0.04 |
| EPS (diluted) | — | 0.09 | 0.13 | 0.07 | — | 0.07 | 0.08 | 0.04 |
| Balance sheet | ||||||||
| Cash & equivalents | $75.47M | $72.00M | $65.98M | $76.25M | $78.44M | $72.00M | $56.55M | $48.19M |
| Receivables | $27.01M | $31.38M | $30.50M | $27.88M | $21.55M | $16.30M | $26.23M | $18.86M |
| Inventory | $84.94M | $85.41M | $82.08M | $78.36M | $78.82M | $71.56M | $78.71M | $84.35M |
| Current assets | $193.07M | $192.73M | $183.27M | $188.50M | $184.35M | $164.41M | $166.43M | $157.81M |
| PP&E, netmay include right-of-use assets (IFRS) | $41.37M | $38.10M | $37.89M | $37.41M | $36.24M | $33.75M | $31.97M | $30.73M |
| Goodwill | $30.31M | $30.31M | $30.31M | $30.31M | $30.31M | $30.31M | $30.31M | $30.31M |
| Intangibles | — | — | — | — | — | $135.04M | $136.83M | $138,623 |
| Total assets | $378.71M | $377.21M | $368.17M | $375.11M | $372.25M | $351.21M | $351.04M | $343.17M |
| Current liabilities | $47.39M | $47.84M | $45.77M | $57.05M | $49.39M | $34.00M | $40.90M | $37.17M |
| Short-term debt | $9.92M | $10.59M | $9.85M | $10.89M | $10.18M | $9.48M | $12.61M | $12.98M |
| Total liabilities | $109.64M | $111.98M | $108.22M | $123.15M | $112.79M | $95.94M | $99.89M | $92.02M |
| Shareholders' equity | $269.07M | $265.23M | $259.95M | $251.96M | $259.46M | $255.27M | $251.15M | $251.15M |
| Shares outstanding | 57.69M | — | — | — | 57.51M | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | $7.57M | $10.42M | $8.02M | -$513,000 | $10.40M | $22.21M | $13.96M | $1.02M |
| Investing cash flow | -$2.77M | -$3.59M | -$2.01M | -$1.46M | -$2.92M | -$2.12M | -$3.01M | -$2.68M |
| Financing cash flow | -$1.18M | -$754,000 | -$16.12M | -$293,000 | -$708,000 | -$4.79M | -$2.68M | -$5.74M |
| Depreciation & amortization | -$9.48M | $3.76M | $3.75M | $3.61M | $4.10M | $3.24M | $3.23M | $3.24M |
| Stock-based compensation | $458,000 | $117,000 | $95,000 | $175,000 | $174,000 | $224,000 | $235,000 | $241,000 |
| Dividends paid | $0 | $0 | $11.53M | $11.53M | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 21 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.